EXEL
Exelixis Inc
stockNASDAQ
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 60.99 | 2026-10-14 | +5.84% | 2.020 |
| 1M | 57.22 | 2026-09-21 | +12.82% | 0.508 |
| 3M | 56.12 | 2026-07-21 | +15.03% | 0.472 |
| 6M | 45.89 | 2026-04-21 | +40.67% | 0.477 |
| 1Y | 36.13 | 2025-10-21 | +78.67% | 0.644 |
| 2Y | 28.66 | 2024-10-21 | +125.24% | — |
| 5Y | 21.33 | 2021-10-21 | +202.65% | 0.582 |
Exelixis Inc (NASDAQ:EXEL) stock price today is $64.56, and today's volume is 1,120,976. EXEL is up 0.256% today. The 30 day average volume is 2.29M. EXEL market cap is $16.00B with 247.78M shares outstanding.